ImmunoCellular Therapeutics (IMUC.OB) issued Cancer Vaccine Technology Patent
OTCBB: IMUC has been issued a US patent relating to a technology for the treatment of cancer for which the company holds an exclusive, worldwide license.
Patent No#7,939,090, entitled “System and method for the treatment of cancer, including cancers of the central nervous system,” covers the combination of a dendritic cell based vaccine combined either before or concurrently with chemotherapy at the recurrence of the disease.
The Bottom Line: IMUC.OB believes that in the treatment of cancer, particularly cancers of the central nervous system such as glioblastoma multiforme (GBM), a dual therapeutic approach that includes the administration of a dendritic cell-based cancer vaccine combined with a regimen of chemotherapy could substantially enhance the clinical efficacy of treatment. The P1 clinical study of ICT-107 in GBM, 16 newly diagnosed patients who received the vaccine in addition to standard of care of surgery, radiation and chemotherapy demonstrated a 1 year overall survival of 100% and a 2 year survival of 80%. IMUC.OB also recently announced the expansion of its P2 trial of ICT-107 from up to 15 clinical centers to 20 or more; which is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study is enrolling patients at medical institutions in collaboration with well known experts and opinion leaders in neuro-oncology at those sites
